SeaSpine to Participate in the Canaccord Musculoskeletal Conference
SeaSpine Holdings Corporation (NASDAQ: SPNE) announced its participation in the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:30 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SeaSpine Holdings Corporation (NASDAQ: SPNE) announced its participation in the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:30 pm ET. A live and archived webcast will be accessible through the SeaSpine website.
SeaSpine specializes in surgical solutions for spinal disorders, providing a portfolio of orthobiologics and spinal implants, as well as surgical navigation systems for neurosurgeons and orthopedic spine surgeons.
Details
News Market Reaction – SPNE
The recorded move for SPNE in the trading session of this news was +1.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will participate in the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022 beginning at 2:30 pm ET.
A live and archived webcast of the event will be available from the Investors section of the SeaSpine website at: www.seaspine.com.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Investor Relations Contact
Leigh Salvo
ir@seaspine.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.